JHVEPhoto AMD ( AMD ) was downgraded at Daiwa Securities on Wednesday, as the investment firm said the recent share price rise could “moderate” in short order. Shares rose 1.3% in premarket trading. Led by Dr. Lisa Su, AMD has “multiple vectors for growth,” but analyst Louis Miscioscia said given the near 150% jump in the stock over the past two months, the growth could “moderate.” Miscioscia lowe...
JHVEPhoto AMD ( AMD ) was downgraded at Daiwa Securities on Wednesday, as the investment firm said the recent share price rise could “moderate” in short order. Shares rose 1.3% in premarket trading. Led by Dr. Lisa Su, AMD has “multiple vectors for growth,” but analyst Louis Miscioscia said given the near 150% jump in the stock over the past two months, the growth could “moderate.” Miscioscia lowered his rating on AMD to Outperfrom from Buy, but he upped his price target to $500 from $250. More on AMD AMD's Next Leg Higher Has Already Started AMD: ~110% Up And Nowhere Near Done (Rating Upgrade) AMD: $600 Target Appears Too Low Marvell in focus as AMD discloses stake SA analyst upgrades/downgrades: AMD, PLTR, VET, PSIX
JHVEPhoto AMD ( AMD ) was downgraded at Daiwa Securities on Wednesday, as the investment firm said the recent share price rise could “moderate” in short order. Shares rose 1.3% in premarket trading. "AMD has multiple vectors for growth, x86 servers to grow over 70% in 2Q, Embedded finally returning to growth, but most importantly sales of Ml355 now and a big ramp for Ml450 in 2H26 and beyond," ana...
JHVEPhoto AMD ( AMD ) was downgraded at Daiwa Securities on Wednesday, as the investment firm said the recent share price rise could “moderate” in short order. Shares rose 1.3% in premarket trading. "AMD has multiple vectors for growth, x86 servers to grow over 70% in 2Q, Embedded finally returning to growth, but most importantly sales of Ml355 now and a big ramp for Ml450 in 2H26 and beyond," analyst Louis Miscioscia wrote in a note to clients. "Even with that, given the appreciation of almost 150% over the past 60 days, near term it could moderate, so we lower our rating to 2/Outperform from 1/Buy." Despite the downgrade, Miscioscia upped his price target to $500 from $250. (This story has been updated to provide additional analyst commentary.) More on AMD AMD's Next Leg Higher Has Already Started AMD: ~110% Up And Nowhere Near Done (Rating Upgrade) AMD: $600 Target Appears Too Low Marvell in focus as AMD discloses stake SA analyst upgrades/downgrades: AMD, PLTR, VET, PSIX
The latest look at wholesale prices points to even higher inflation in the next month or two. The producer price index jumped 1.4% in April to mark the biggest rise in four years.
The latest look at wholesale prices points to even higher inflation in the next month or two. The producer price index jumped 1.4% in April to mark the biggest rise in four years.
JHVEPhoto/iStock Editorial via Getty Images Micron's ( MU ) performance over the past three, six, nine, and twelve months alone leaves no doubt about how great it has been to invest in this company. Seeking Alpha And at this rate, it seems very clear that the company that is now worth ~$896 billion at the time of writing is taking major steps toward joining the trillion-dollar valuation group. Alt...
JHVEPhoto/iStock Editorial via Getty Images Micron's ( MU ) performance over the past three, six, nine, and twelve months alone leaves no doubt about how great it has been to invest in this company. Seeking Alpha And at this rate, it seems very clear that the company that is now worth ~$896 billion at the time of writing is taking major steps toward joining the trillion-dollar valuation group. Although Micron has an extremely bullish quant rating and numerous bullish headlines around its name as a main beneficiary of the AI infrastructure bottleneck, it leaves me somewhat torn that the sell-side consensus points to a potential downside of 27.8% in the thesis today, at an implied share price of $573 per share for MU. Seeking Alpha As Micron currently has 1.12 billion shares outstanding, having a market cap of $1 trillion would imply something close to $888 per share. The consensus that the company is now worth around $642 billion seems to me to be confirmation that Micron is still not widely accepted, or properly priced, as a structurally sound earnings thesis, including my premise in my l ast coverage of the thesis . That being said, in this article, my goal is to bring up some points, such as the possibility of structurally higher base earnings, along with the growing strategic importance of memory in the age of AI. Doing an exercise of "owner earnings" anchored in FY28—a year that the consensus today incorporates as some normalization of the memory cycle, but still suggests extremely robust cash generation after heavy investments in CapEx—I believe that the market may still be using a framework that is too old to evaluate Micron. Micron Still Trades Like a Cyclical It may sound repetitive at this point in Micron’s rally to say that the thesis is cyclical. But trading at 13.7x FY26 earnings, according to YCharts, it is undeniable that even jumping ~777% in the last twelve months, the market still treats Micron's thesis as cyclical. Data by YCharts Most of the time,...
JHVEPhoto/iStock Editorial via Getty Images Micron's ( MU ) performance over the past three, six, nine, and twelve months alone leaves no doubt about how great it has been to invest in this company. Seeking Alpha And at this rate, it seems very clear that the company that is now worth ~$896 billion at the time of writing is taking major steps toward joining the trillion-dollar valuation group. Alt...
JHVEPhoto/iStock Editorial via Getty Images Micron's ( MU ) performance over the past three, six, nine, and twelve months alone leaves no doubt about how great it has been to invest in this company. Seeking Alpha And at this rate, it seems very clear that the company that is now worth ~$896 billion at the time of writing is taking major steps toward joining the trillion-dollar valuation group. Although Micron has an extremely bullish quant rating and numerous bullish headlines around its name as a main beneficiary of the AI infrastructure bottleneck, it leaves me somewhat torn that the sell-side consensus points to a potential downside of 27.8% in the thesis today, at an implied share price of $573 per share for MU. Seeking Alpha As Micron currently has 1.12 billion shares outstanding, having a market cap of $1 trillion would imply something close to $888 per share. The consensus that the company is now worth around $642 billion seems to me to be confirmation that Micron is still not widely accepted, or properly priced, as a structurally sound earnings thesis, including my premise in my l ast coverage of the thesis . That being said, in this article, my goal is to bring up some points, such as the possibility of structurally higher base earnings, along with the growing strategic importance of memory in the age of AI. Doing an exercise of "owner earnings" anchored in FY28—a year that the consensus today incorporates as some normalization of the memory cycle, but still suggests extremely robust cash generation after heavy investments in CapEx—I believe that the market may still be using a framework that is too old to evaluate Micron. Micron Still Trades Like a Cyclical It may sound repetitive at this point in Micron’s rally to say that the thesis is cyclical. But trading at 13.7x FY26 earnings, according to YCharts, it is undeniable that even jumping ~777% in the last twelve months, the market still treats Micron's thesis as cyclical. Data by YCharts Most of the time,...
Solskin/DigitalVision via Getty Images Introduction May 5, 2026 was ugly for GeneDX ( WGS ) holders. Stock crashed roughly 50%, from $68 down to about $34 in a single session, after Q1 came short on both top and bottom line and management cut FY26 revenue guide to $475-490M from $540-555M. Sell-side analysts reacted hard. BTIG took its target from $170 down to $90. Wells Fargo went $155 to $75. Gu...
Solskin/DigitalVision via Getty Images Introduction May 5, 2026 was ugly for GeneDX ( WGS ) holders. Stock crashed roughly 50%, from $68 down to about $34 in a single session, after Q1 came short on both top and bottom line and management cut FY26 revenue guide to $475-490M from $540-555M. Sell-side analysts reacted hard. BTIG took its target from $170 down to $90. Wells Fargo went $155 to $75. Guggenheim, $100 to $70. TD Cowen, $60 to $55.But every single one of them kept a Buy rating. That says the sell-side does not think the long story is over. We think the same as the 34% YoY growth on volume is the headline that no one is talking about. WGS Price Action (Seeking Alpha) Volume actually beat company's own internal forecast. Entire revenue miss is related to mix dynamics inside exome and genome portfolio plus weakness in two non-core lines (Fabric Genomics, biopharma data). No change in pricing and no contraction in payer coverage. Q1 Was Strong On Volume, Weak On Revenue Q1 headline numbers were as follows: revenue $102 million, adjusted gross margin 69%, adjusted net loss $8 million. Exome and genome revenue grew 27% YoY to $91 million. Volume grew 34% YoY to 27,488 tests. Blended ARR was roughly $3,300, around $200 below internal plan. Volume actually beat the company's own internal forecast we want to stress. This is the most important data point of Q1, in our view. E&G volume growth (GeneDx Q1 2026 Earnings Presentation) Revenue shortfall broke into two pieces. 1- roughly $5.5 million from a lower blended ARR. Reason: outpatient genome was about 40% of outpatient volume in Q1, roughly double the prior-year mix. 2- roughly $6.5 million from non-core lines (Fabric, biopharma and data, a smaller miss on multi-gene panels). And than within the non-core piece, Fabric alone was about $2.5 million of that. EG Revenue (GeneDx Q1 2026 Earnings Presentation) This is not a demand miss is the point we want to make. Outpatient exome ARR is closer to $4,000 per test after...
CDW ( CDW ) said its board of directors has authorized a $1B increase to the company’s share repurchase program. The authorization is incremental to the approximately $484M remaining from the previous repurchase program as of March 31, 2026. More on CDW Corporation CDW Corporation: A 20% Decline Could Be A Gift For Investors (Upgrade) CDW Corporation (CDW) Q1 2026 Earnings Call Transcript CDW Corp...
CDW ( CDW ) said its board of directors has authorized a $1B increase to the company’s share repurchase program. The authorization is incremental to the approximately $484M remaining from the previous repurchase program as of March 31, 2026. More on CDW Corporation CDW Corporation: A 20% Decline Could Be A Gift For Investors (Upgrade) CDW Corporation (CDW) Q1 2026 Earnings Call Transcript CDW Corporation 2026 Q1 - Results - Earnings Call Presentation 19 of 20 S&P 500 tech companies beat EPS estimates: Earnings scorecard CDW outlines $100M-$200M geared for growth run-rate improvements into 2027-2028 while maintaining 200-300 bps market outperformance target
TTEC ( NASDAQ: TTEC ) on Wednesday said that its unit TTEC Digital signed a strategic collaboration agreement with Amazon Web Services (AWS) to accelerate adoption of Amazon Connect through AI-powered customer experience services. The company said the agreement will focus on helping organizations modernize legacy contact center platforms using AI, automation, and real-time data capabilities within...
TTEC ( NASDAQ: TTEC ) on Wednesday said that its unit TTEC Digital signed a strategic collaboration agreement with Amazon Web Services (AWS) to accelerate adoption of Amazon Connect through AI-powered customer experience services. The company said the agreement will focus on helping organizations modernize legacy contact center platforms using AI, automation, and real-time data capabilities within Amazon Connect. TTEC Digital said the collaboration includes intelligent self-service and agent assist offerings and is intended to reduce the cost and complexity of customer experience transformations while speeding deployment of AI tools. The company did not disclose financial terms of the agreement. TTEC +1.64% premarket to $2.48. Source: Press Release More on TTEC Holdings TTEC reiterates 2026 guidance while targeting over 40% offshore mix by year-end TTEC Holdings Non-GAAP EPS of $0.15 misses by $0.09, revenue of $496.2M beats by $2.51M
Yields Spike As Producer Prices Explode Higher In April After yesterday's hotter than expected CPI (driven in large part by Energy, but seeing some contagion into Services costs), this morning's Producer Price print for April was expected to show a major surge in annual wholesale inflation. With the eight straight monthly increase, PPI rose by a massive 1.4% MoM (vs +0.5% MoM exp) - the biggest Mo...
Yields Spike As Producer Prices Explode Higher In April After yesterday's hotter than expected CPI (driven in large part by Energy, but seeing some contagion into Services costs), this morning's Producer Price print for April was expected to show a major surge in annual wholesale inflation. With the eight straight monthly increase, PPI rose by a massive 1.4% MoM (vs +0.5% MoM exp) - the biggest MoM jump since March 2022, lifting PPI by a stunning 6.0% YoY (vs 4.8% YoY exp). That is the hottest PPI YoY since Dec 2022... Source: Bloomberg Services and Energy saw the biggest rise (while construction costs actually deflated very modestly)... Core Producer Prices spiked 1.0% MoM (more than triple the +0.3% exp) smashing Core PPI YoY up 5.2% (also the hottest since Dec 2022)... Source: Bloomberg And finally, one could argue this is as bad as it gets for the energy component as oil prices have stabilized... Source: Bloomberg But of course, the pipeline of those energy costs is perhaps only just starting to trickle into the rest of the economy. PPI triggered a spike in 2Y yields... Now back above 4.00% at their highest since March with the market now pricing in a 50% chance of one rate-hike in 2026... It appears any chance of Warsh cutting rates (as per Trump's expectations) are off the table... for now. Finally, there is perhaps a silver lining from this ugly PPI report. Other than airfares (which rose 3%) the components that feed through into PCE inflation were pretty tame ; portfolio management fees dropped 2.4% and the various medical-care components showed a maximum rise of 0.3%. That may mitigate the impact of the report , but it’s still hard to totally ignore the risk that inflation becomes a more pressing concern moving forward. Tyler Durden Wed, 05/13/2026 - 08:40